{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:05:16Z","timestamp":1789769116376,"version":"4.0.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Am Acad Orthop Surg","JAAOS"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ondansetron is a cornerstone medication for preventing postoperative nausea and vomiting (PONV) in numerous international guidelines. Ondansetron oral soluble pellicles (OSP) represent a needle-free PONV prophylaxis administration regimen with favorable practicality. We conducted this study to investigate the optimal dosing regimen by comparing the efficacy and safety of different doses of ondansetron OSP for preventing PONV following total joint arthroplasty (TJA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is a randomized, controlled, and double-masked clinical trial. A total of 198 patients were randomized into three groups: the control group receiving two placebo pellicles orally 1 hour before anesthesia induction; the preoperation (Preop) 8-mg group receiving one ondansetron OSP (8 mg) plus one placebo pellicles; and the Preop 16-mg group receiving two ondansetron OSP (16 mg total). The primary outcome was the incidence and severity (measured by visual analog scale scores) of PONV within 48 hours after TJA. The secondary outcome included the frequency of tramadol and metoclopramide and the occurrence of ondansetron adverse drug reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Both 8 and 16 mg ondansetron OSP markedly reduced PONV incidence. Compared with the Preop 8-mg group, the Preop 16-mg group demonstrated markedly lower PONV incidence and reduced nausea severity at all postoperative time points relative to the control group, with a greater absolute risk reduction, indicating superior prophylactic efficacy. Adverse drug reactions rates did not differ markedly between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Compared with placebo, ondansetron OSP effectively reduces the incidence of PONV following TJA and demonstrates a favorable safety profile. The findings suggest a trend toward better efficacy with a preoperative oral dose of 16 mg compared with 8 mg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration:<\/jats:title>\n                    <jats:p>Chinese Clinical Trial Registry, ChiCTR2500097588. Registered on 21 February 2025.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5435\/jaaos-d-25-01069","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:00:08Z","timestamp":1769112008000},"page":"e2771-e2778","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Ondansetron Oral Soluble Pellicles Effectively Reduce the Incidence of Postoperative Nausea and Vomiting Following Primary Total Joint Arthroplasty: A Randomized Controlled Trial"],"prefix":"10.5435","volume":"34","author":[{"given":"Yinghao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangjie","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongke","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1956-0592","authenticated-orcid":false,"given":"Haoyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"R1-20260918","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2106\/JBJS.17.01617","article-title":"Projected volume of primary total joint arthroplasty in the U.S., 2014 to 2030","volume":"100","author":"Sloan","year":"2018","journal-title":"J Bone Joint Surg Am"},{"key":"R2-20260918","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2106\/JBJS.18.00128","article-title":"Finding the optimal regimen for oral tranexamic acid administration in primary total hip arthroplasty: A randomized controlled trial","volume":"101","author":"Wang","year":"2019","journal-title":"J Bone Joint Surg Am"},{"key":"R3-20260918","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev-neuro-080317-061522","article-title":"Endogenous and exogenous opioids in pain","volume":"41","author":"Corder","year":"2018","journal-title":"Annu Rev Neurosci"},{"key":"R4-20260918","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/bja\/aes276","article-title":"Evidence-based analysis of risk factors for postoperative nausea and vomiting","volume":"109","author":"Apfel","year":"2012","journal-title":"Br J Anaesth"},{"key":"R5-20260918","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1186\/s12884-023-06100-8","article-title":"Efficacy and safety of tranexamic acid in prevention of postpartum hemorrhage: A systematic review and meta-analysis of 18,649 patients","volume":"23","author":"Al-Dardery","year":"2023","journal-title":"BMC Pregnancy Childbirth"},{"key":"R6-20260918","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1213\/ANE.0000000000004833","article-title":"Fourth consensus guidelines for the management of postoperative nausea and vomiting","volume":"131","author":"Gan","year":"2020","journal-title":"Anesth Analg"},{"key":"R7-20260918","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejphar.2013.10.037","article-title":"Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting","volume":"722","author":"Horn","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"R8-20260918","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/bja\/aer505","article-title":"Simplified postoperative nausea and vomiting impact scale for audit and post-discharge review","volume":"108","author":"Myles","year":"2012","journal-title":"Br J Anaesth"},{"key":"R9-20260918","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1213\/01.ane.0000295230.55439.f4","article-title":"Society for ambulatory anesthesia guidelines for the management of postoperative nausea and vomiting","volume":"105","author":"Gan","year":"2007","journal-title":"Anesth Analg"},{"key":"R10-20260918","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bpa.2020.10.009","article-title":"What is the ideal combination antiemetic regimen?","volume":"34","author":"Uribe","year":"2020","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"R11-20260918","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4103\/0019-5049.138977","article-title":"Efficacy of orally disintegrating film of ondansetron versus intravenous ondansetron in prophylaxis of postoperative nausea and vomiting in patients undergoing elective gynaecological laparoscopic procedures: A prospective randomised, double-blind placebo-controlled study","volume":"58","author":"Hegde","year":"2014","journal-title":"Indian J Anaesth"},{"key":"R12-20260918","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12885-024-13406-z","article-title":"Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting","volume":"25","author":"Sun","year":"2025","journal-title":"BMC Cancer"},{"key":"R13-20260918","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1001\/jama.2022.21022","article-title":"Guidelines for reporting outcomes in trial reports: The CONSORT-outcomes 2022 extension","volume":"328","author":"Butcher","year":"2022","journal-title":"JAMA"},{"key":"R14-20260918","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa032196","article-title":"A factorial trial of six interventions for the prevention of postoperative nausea and vomiting","volume":"350","author":"Apfel","year":"2004","journal-title":"N Engl J Med"},{"key":"R15-20260918","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1213\/ANE.0000000000000002","article-title":"Consensus guidelines for the management of postoperative nausea and vomiting","volume":"118","author":"Gan","year":"2014","journal-title":"Anesth analgesia"},{"key":"R16-20260918","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/MJT.0000000000000174","article-title":"Bioequivalence of ondansetron oral soluble film 8 mg (ZUPLENZ) and ondansetron orally disintegrating tablets 8 mg (ZOFRAN) in healthy adults","volume":"22","author":"Dadey","year":"2015","journal-title":"Am J Ther"},{"key":"R17-20260918","first-page":"4621","article-title":"Pharmacokinetics and bioavailability study of two ondansetron oral soluble film formulations in fasting healthy male Chinese volunteers","volume":"9","author":"Zhu","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"R18-20260918","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12871-020-01214-4","article-title":"Oral mosapride can provide additional anti-emetic efficacy following total joint arthroplasty under general anesthesia: A randomized, double-blinded clinical trial","volume":"20","author":"Xie","year":"2020","journal-title":"BMC Anesthesiol"},{"key":"R19-20260918","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40360-024-00735-9","article-title":"Comparison of three different prophylactic treatments for postoperative nausea and vomiting after total joint arthroplasty under general anesthesia: A randomized clinical trial","volume":"25","author":"Xie","year":"2024","journal-title":"BMC Pharmacol Toxicol"},{"key":"R20-20260918","doi-asserted-by":"crossref","first-page":"202","DOI":"10.7602\/jmis.2024.27.4.202","article-title":"Comparison of efficacy and safety between palonosetron and ondansetron to prevent postoperative nausea and vomiting in patients undergoing laparoscopic surgery: A systematic review and meta-analysis","volume":"27","author":"Kumar","year":"2024","journal-title":"J Minim Invasive Surg"},{"key":"R21-20260918","doi-asserted-by":"crossref","first-page":"e0186006","DOI":"10.1371\/journal.pone.0186006","article-title":"Comparative efficacy of ramosetron and ondansetron in preventing postoperative nausea and vomiting: An updated systematic review and meta-analysis with trial sequential analysis","volume":"12","author":"Yokoi","year":"2017","journal-title":"PLoS One"},{"key":"R22-20260918","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajem.2024.08.011","article-title":"The effect of intravenous ondansetron on QT interval in the emergency department","volume":"85","author":"Y\u00fcr\u00fck M\u0131s\u0131rl\u0131o\u011flu","year":"2024","journal-title":"Am J Emerg Med"},{"key":"R23-20260918","doi-asserted-by":"crossref","first-page":"102971","DOI":"10.1016\/j.amsu.2021.102971","article-title":"Investigation role of ondansetron on long QT interval among non-cardiac patients","volume":"71","author":"Tabrizi","year":"2021","journal-title":"Ann Med Surg (Lond)"}],"container-title":["Journal of the American Academy of Orthopaedic Surgeons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-25-01069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:00:30Z","timestamp":1789768830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-25-01069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":23,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5435\/jaaos-d-25-01069","relation":{},"ISSN":["1067-151X","1940-5480"],"issn-type":[{"value":"1067-151X","type":"print"},{"value":"1940-5480","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"2025-08-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}